Clinical Trial Detail

NCT ID NCT03918499
Title IRX-2, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer
Recruitment Suspended
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Cyclophosphamide + IRX-2 + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.